Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ryan Bariola

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Annals of Internal Medicine|April 3, 2023
Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort StudyKevin E Kip, Erin K McCreary, Kevin Collins, et al.
Learning Health Systems|July 21, 2022
A learning health system approach to the COVID-19 pandemic: System-wide changes in clinical practice and 30-day mortality among hospitalized patientsErin K McCreary, Kevin E Kip, J Ryan Bariola, et al.
Open Forum Infectious Diseases|November 3, 2022
Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant EraErin K McCreary, Kevin E Kip, Kevin Collins, et al.
Open Forum Infectious Diseases|June 2, 2023
Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody TherapyJana L Jacobs, Ghady Haidar, Asma Naqvi, et al.
Open Forum Infectious Diseases|July 12, 2021
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionJ Ryan Bariola, Erin K McCreary, Richard J Wadas, et al.
Contemporary Clinical Trials|December 13, 2021
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 daysErin K McCreary, J Ryan Bariola, Tami Minnier, et al.
JAMA Network Open|April 12, 2022
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19Erin K McCreary, J Ryan Bariola, Richard J Wadas, et al.
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Annals of Internal Medicine|April 3, 2023
Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort StudyKevin E Kip, Erin K McCreary, Kevin Collins, et al.
Learning Health Systems|July 21, 2022
A learning health system approach to the COVID-19 pandemic: System-wide changes in clinical practice and 30-day mortality among hospitalized patientsErin K McCreary, Kevin E Kip, J Ryan Bariola, et al.
Open Forum Infectious Diseases|November 3, 2022
Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant EraErin K McCreary, Kevin E Kip, Kevin Collins, et al.
Open Forum Infectious Diseases|June 2, 2023
Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody TherapyJana L Jacobs, Ghady Haidar, Asma Naqvi, et al.
Open Forum Infectious Diseases|July 12, 2021
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionJ Ryan Bariola, Erin K McCreary, Richard J Wadas, et al.
Contemporary Clinical Trials|December 13, 2021
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 daysErin K McCreary, J Ryan Bariola, Tami Minnier, et al.
JAMA Network Open|April 12, 2022
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19Erin K McCreary, J Ryan Bariola, Richard J Wadas, et al.
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Pageof 3